Impact of clinical pharmacist’s interventions on clinical outcomes in appropriate use of colistin: a prospective pre-post intervention study

References

• Loho T, Dharmayanti A. Colistin: an antibiotic and its role in multiresistant gram-negative infections. Acta Med Indones. 2015;47(2):157–168.
   PubMed Web of Science ®Google Scholar
• El-Sayed Ahmed M-G, Zhong L-L, Shen C, et al. Colistin and its role in the era of antibiotic resistance: an extended review (2000–2019). Emerg Microbes Infect. 2020;9(1):868–885.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Saffioti C, Losito AR, et al. Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist. 2020;20:43–49.
   PubMed Web of Science ®Google Scholar
• Spapen H, Jacobs R, Van Gorp V, et al. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1(1):1–7.
   PubMedGoogle Scholar
• Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10(1):1–13.
   Web of Science ®Google Scholar
• Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J, Cars O, et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the prato polymyxin consensus. Lancet Infect Dis. 2015;15(2):225–234.
   PubMed Web of Science ®Google Scholar
• Kassamali Z, Rotschafer JC, Jones RN, et al. Polymyxins: wisdom does not always come with age. Clin Infect Dis. 2013;57(6):877–883.
   PubMed Web of Science ®Google Scholar
• Biswas S, Brunel J-M, Dubus J-C, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10(8):917–934.
   PubMed Web of Science ®Google Scholar
• Ortwine JK, Kaye KS, Li J, et al. Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy. 2015;35(1):11–16.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of america (IDSA), international society for anti‐infective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10–39.
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Thamlikitkul V, Giamarellos-Bourboulis EJ, Forrest A, Paterson DL, et al. Dosing guidance for intravenous colistin in critically ill patients. Clin Infect Dis. 2017;64(5):565–571
   Google Scholar
• Zabidi MS, Abu Bakar R, Musa N, et al. Population pharmacokinetics of colistin methanesulfonate sodium and colistin in critically ill patients: a systematic review. Pharmaceuticals. 2021;14(9):903.
   Web of Science ®Google Scholar
• Moni M, Sudhir AS, Dipu T, et al. Clinical efficacy and pharmacokinetics of colistimethate sodium and colistin in critically ill patients in an ındian hospital with high endemic rates of multidrug-resistant gram-negative bacterial infections: a prospective observational study. Int J Infect Dis. 2020;100:497–506.
   PubMed Web of Science ®Google Scholar
• Bellos I, Pergialiotis V, Frountzas M, et al. Efficacy and safety of colistin loading dose: a meta-analysis. J Antimicrob Chemother. 2020;75(7):1689–1698.
   PubMed Web of Science ®Google Scholar
• Raosoft Inc. 2004. RaoSoft® sample size calculator. [cited 2020 Jan 1]. http://www.raosoft.com/samplesize.html.
   Google Scholar
• Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
   PubMed Web of Science ®Google Scholar
• Jung S, Chung EK, Jun MS, et al. Differences in colistin administration and bacterial and treatment outcomes in critically ill patients. Sci Rep. 2019;9(1):1–11.
   PubMedGoogle Scholar
• Gibson GA, Bauer SR, Neuner EA, et al. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2015;60(1):431–436.
   PubMed Web of Science ®Google Scholar
• Kdigo A, Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138.
   Google Scholar
• Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and laboratory standards ınstitute and european committee on antimicrobial susceptibility testing position statements on polymyxin B and colistin clinical breakpoints. Clin Infect Dis. 2020;71(9):e523–e529.
   PubMed Web of Science ®Google Scholar
• Makris K, Spanou L. Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev. 2016;37(2):85.
   PubMedGoogle Scholar
• World Health Organization. Antimicrobial resistance surveillance in Europe 2022–2020 data. 2022.
   Google Scholar
• Paul M, Carrara E, Retamar P, et al. European society of clinical microbiology and ınfectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by european society of intensive care medicine). Clin Microbiol Infect. 2022;28(4):521–547.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–1341.
   PubMed Web of Science ®Google Scholar
• Özkarakaş H, Köse I, Zincircioğlu Ç, et al. Risk factors for colistin-associated nephrotoxicity and mortality in critically ill patients. Turk J Med Sci. 2017;47(4):1165–1172.
   PubMed Web of Science ®Google Scholar
• Almutairy R, Aljrarri W, Noor A, et al. Impact of colistin dosing on the incidence of nephrotoxicity in a tertiary care hospital in Saudi Arabia. Antibiotics. 2020;9(8):485.
   Google Scholar
• Vazin A, Birjand MM, Darake M. Evaluation of vancomycin therapy in the adult ICUs of a teaching hospital in Southern Iran. Drug Healthc Patient Saf. 2018;10:21.
   PubMed Web of Science ®Google Scholar
• Messina A, Brink A, Richards G, et al. Opportunities to optimise colistin stewardship in hospitalised patients in South Africa: results of a multisite utilisation audit. S Afr Med J. 2018;108(1):28–32.
   Web of Science ®Google Scholar
• Labuschagne Q, Schellack N, Gous A, et al. Colistin: adult and paediatric guideline for South Africa, 2016: guideline. S Afr J Infect Dis. 2016;31(1):3–7.
   Web of Science ®Google Scholar
• Visser Kift E, Maartens G, Bamford C. Systematic review of the evidence for rational dosing of colistin. S Afr Med J. 2014;104(3):183–186.
   PubMed Web of Science ®Google Scholar
• Katip W, Yoodee J, Uitrakul S, et al. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing enterobacteriaceae. Sci Reports. 2021;11(1):1–8.
   PubMed Web of Science ®Google Scholar
• Cai Y, Leck H, Tan RW, et al. Clinical experience with high-dose polymyxin B against carbapenem-resistant gram-negative bacterial ınfections a cohort study. Antibiotics. 2020;9(8):451.
   Google Scholar
• Katip W, Meechoui M, Thawornwittayakom P, et al. Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study. J Intensive Care Med. 2019;34(11–12):996–1002.
   PubMed Web of Science ®Google Scholar
• Gauthier TP, Wolowich WR, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012;56(5):2392–2396.
   PubMed Web of Science ®Google Scholar
• Phe K, Lee Y, McDaneld PM, et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother. 2014;58(5):2740–2746.
   PubMed Web of Science ®Google Scholar
• Temocin F, Erdinc S, Tulek N, et al. Incidence and risk factors for colistin-associated nephrotoxicity. Jpn J Infect Dis. 2015;68(4):318–320.
   PubMed Web of Science ®Google Scholar
• Colpan A, Akinci E, Erbay A, et al. Evaluation of risk factors for mortality in intensive care units: a prospective study from a referral hospital in Turkey. Am J Infect Control. 2005;33(1):42–47.
   PubMed Web of Science ®Google Scholar
• Bauer M, Gerlach H, Vogelmann T, et al. Mortality in sepsis and septic shock in Europe, North america and Australia between 2009 and 2019—results from a systematic review and meta-analysis. Crit Care. 2020;24(1):1–9.
   PubMed Web of Science ®Google Scholar